

Embargoed: 0700hrs, 3 May 2006

Akers Biosciences, Inc.
("Akers" or the "Company")

Akers Biosciences Receives FDA Clearance to Market its Rapid Alcohol Breathalyzers

Thorofare, NJ, USA—3 May, 2006--Akers Biosciences Inc. (LSE:AKR) is pleased to announce today that it has received market clearance from the U.S. Food and Drug Administration ("FDA") for its rapid alcohol breathalyzers. Four different versions of the product were cleared, each detecting a specific amount of breath alcohol. The Company markets its breathalyzers under the BreathScan and Breath Alcohol Check brands.

The Company's breathalyzers provide reliable indicators of alcohol present in a person's breath, which is, in turn, related to a person's blood alcohol level. The single-use devices are portable and low-cost, and can be read visually or with the use of an inexpensive electronic reader developed by the Company. The Company's breathalyzers are used in many different situations, including, among others, law enforcement, transport industries, education sectors, employee screening, and personal use. Akers is the only manufacturer of portable alcohol breathalyzers in the United States and, following the acquisition of WNCK, Inc in February, is also the leading United States distributor in this field.

The FDA has recently begun to regulate alcohol breathalyzers as medical devices, and now requires regulatory clearance that indicates that the breathalyzer is safe and effective. In addition, all alcohol breathalyzers must now be manufactured according to Good Manufacturing Practices (GMP). The Akers products are one of the first such devices to be cleared by the FDA. In fact, as of today, there are only two other breathalyzer products that have been cleared by the FDA, and both are electronic devices.

The market clearance is key in that many US government agencies, including the US military, require that alcohol breathalyzers are FDA-cleared prior to purchase. With the benefit of this clearance now obtained, the Company expects it will be able to penetrate new areas of the market not previously possible prior to this point.

Dr. Ray Akers, CEO of Akers Biosciences said, "We are delighted to be able to announce this market clearance today. This is a significant milestone in the expansion of our breathalyzer business. We are ahead of the competition with respect to regulatory clearances, and this should have a positive impact on our market penetration."

For further information, please contact,

Dr. Ray Akers
Paul Freedman

Chief Executive Officer, Akers Biosciences, Inc.
Chief Financial Officer, Akers Biosciences, Inc.

020 7917 9476
001 856 848 8698

Bill Roberts

CTC, Inc.

001 937 434 2700

Akers Biosciences

Akers Biosciences, Inc. develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the patient or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. Akers has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com.